EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Treatment effects of elexacaftor/tezacaftor/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variant

Moshe Heching, Michal Shteinberg, Inbal Golan-Tripto, Galit Livnat-Levanon, Karin Yaacoby-Bianu, Liora Boehm Cohen, Guy Hazan, Liora Slomianski, Dario Prais, Huda Mussaffi, Joel Weinberg, Mordechai R Kramer

Journal of Cystic Fibrosis · 2025

DOI: 10.1016/j.jcf.2024.11.010 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Moshe Heching und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Institute and Adult CF Center, Rabin Medical Center, Petach Tikva, Israel; School of Medicine, Faculty of Medical and Health Sciences, Te…. Hauptthemen laut MEDLINE: Aminophenols, Benzodioxoles, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The splice variant 3849+10kbC->T (c.3717+12191C>T) (3849 variant) is a residual function CFTR variant, characterized by insertion of an in-frame stop codon into most CFTR transcripts. Both ivacaftor (Iva) and tezacaftor/ivacaftor (Tez/Iva) have been approved for people with CF (pwCF) carrying the 3849 variant. In-vitro studies for elexacaftor/tezacaftor/ivacaftor (ETI) did not include the 3849 variant as responsive to ETI. We present the clinical effectiveness of ETI in pwCF homozygous for the 3849 variant or heterozygous for 3849 and class I variants previously treated with Iva or Tez/Iva. METHODS: We conducted a multi-center observational study of pwCF homozygous for the 3849 variant or heterozygous for 3849 and class I variants who were transitioned from Iva or Tez/Iva to ETI. We collected clinical data, including sweat chloride concentrations, pulmonary function tests, BMI and intravenous antibiotic treatments. RESULTS: We identified nine pwCF heterozygous for 3849 and class I variants and one pwCF homozygous for the 3849 variant. Prior to transitioning to ETI, nine pwCF were treated with Tez/Iva and one with Iva. Compared to baseline, median sweat chloride concentration declined from 48 to 35 mEq/L (p = 0.009). Median FEV1 increased from 53 % to 65 % (p = 0.006). Pulmonary exacerbations requiring intravenous antibiotics declined from mean 1.4 to 0.6 in the twelve months before and after ETI. CONCLUSIONS: We demonstrate the clinical effectiveness of ETI in pwCF carrying the 3849 variant, in excess of the response to Iva or Iva/Tez. Our results provide preliminary support for clinical use of ETI in pwCF carrying the 3849+10kbC->T variant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminophenolsBenzodioxolesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorIndolesPyrazolesPyridinesPyrrolidinesAdolescentAdultChildFemaleHumansMaleYoung AdultChloride Channel AgonistsDrug CombinationsHeterozygoteQuinolonesTreatment OutcomeQuinolines

Stichwörter der Autor:innen

3849+10kbC->T variantCFTR modulatorsElexacaftorResidual function variant

Substanzen

AminophenolsBenzodioxolesChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorDrug Combinationselexacaftorelexacaftor, ivacaftor, tezacaftor drug combinationIndolesivacaftorPyrazoles

Autor:innen und Institutionen

  • Pulmonology Institute and Adult CF Center, Rabin Medical Center, Petach Tikva, Israel; School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. Electronic address: moshehe@clali…
  • Pulmonology Institute and CF Center, Carmel Medical Center, Haifa, Israel; Technion-Israel Institute of Technology, Haifa, Israel.
  • Pediatric Pulmonary Unit, Soroka University Medical Center, Beer Sheva, Israel; Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • Pulmonology Institute and Adult CF Center, Rabin Medical Center, Petach Tikva, Israel.
  • Pediatric Pulmonology Institute and CF Center, Schneider Children's Medical Center, Petach Tikva, Israel; School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Pulmonology Institute and Adult CF Center, Rabin Medical Center, Petach Tikva, Israel; School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Zitieren

APA

Heching, M., Shteinberg, M., Golan-Tripto, I., Livnat-Levanon, G., Yaacoby-Bianu, K., Boehm Cohen, L., Hazan, G., Slomianski, L., Prais, D., Mussaffi, H., Weinberg, J., & Kramer, M. R. (2025). Treatment effects of elexacaftor/tezacaftor/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variant. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.11.010

Vancouver

Heching M, Shteinberg M, Golan-Tripto I, Livnat-Levanon G, Yaacoby-Bianu K, Boehm Cohen L, et al. Treatment effects of elexacaftor/tezacaftor/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variant. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2024.11.010

BibTeX
@article{Heching2025,
  author = {Heching, Moshe and Shteinberg, Michal and Golan-Tripto, Inbal and Livnat-Levanon, Galit and Yaacoby-Bianu, Karin and Boehm Cohen, Liora and Hazan, Guy and Slomianski, Liora and Prais, Dario and Mussaffi, Huda and Weinberg, Joel and Kramer, Mordechai R},
  title = {Treatment effects of elexacaftor/tezacaftor/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variant},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  doi = {10.1016/j.jcf.2024.11.010}
}
Kostenlos starten →